Sugammadex basics

What it is (and what it isn’t)

• Sugammadex is a selective reversal agent for aminosteroid neuromuscular blockers: mainly rocuronium, also vecuronium.
• It works by binding (encapsulating) free rocuronium/vecuronium in plasma, reducing the amount available at the neuromuscular junction.
• It does NOT reverse suxamethonium or benzylisoquinoliniums (e.g. atracurium, cisatracurium).
• Reversal is usually faster and more reliable than neostigmine for rocuronium, but it is not a substitute for good monitoring.

When you might use it (common new-starter scenarios)

• Routine reversal after rocuronium/vecuronium when you want rapid, predictable recovery.
• Deep block at the end of surgery (e.g. laparoscopic cases) where neostigmine would be slow or unreliable.
• ‘Can’t intubate, can’t ventilate’ or failed airway after rocuronium: can be considered as part of a rescue plan, but does not fix hypoxia—oxygenation and airway management remain the priority.
• Need for rapid return of spontaneous breathing at the end of a short case where rocuronium was used.

Dosing (tie it to nerve stimulator findings)

• Always base dose on objective neuromuscular monitoring where possible (e.g. train-of-four, TOF).
• 2 mg/kg IV: when there is moderate block (TOF count 2 or more).
• 4 mg/kg IV: when there is deep block (post-tetanic count 1–2, or TOF 0 but some post-tetanic response).
• 16 mg/kg IV: immediate reversal after a large rocuronium dose (e.g. 1.2 mg/kg) when you need urgent reversal soon after administration—rare outside emergencies.
• Dose by actual body weight unless local policy says otherwise; if unsure in obesity, ask a senior and use quantitative monitoring to guide recovery.

How to give it (practical steps)

• Confirm the relaxant used: rocuronium or vecuronium (check chart, syringe label, and timing).
• Assess depth of block with a nerve stimulator (ideally quantitative TOF ratio monitoring).
• Give as an IV bolus; ensure a working IV line and flush well.
• Continue ventilation and anaesthesia until you have clear evidence of recovery (do not assume ‘drug given = safe to extubate’).
• Re-check TOF ratio after dosing; aim for TOF ratio ≥ 0.9 before extubation (quantitative monitor preferred).

Monitoring and extubation safety

• Residual neuromuscular block can still occur (especially if under-dosed, wrong drug, or no monitoring).
• Use quantitative neuromuscular monitoring if available; clinical tests alone are unreliable.
• Before extubation: TOF ratio ≥ 0.9, adequate tidal volumes, sustained head lift/hand grip (supportive but not definitive), and appropriate level of consciousness/analgesia.
• After extubation: watch for upper airway obstruction, hypoventilation, desaturation—treat early and consider residual block if unexplained.

Side effects and important cautions

• Anaphylaxis can occur (rare but serious): treat as per anaphylaxis guidelines; document and refer for allergy testing.
• Bradycardia has been reported: monitor ECG and be ready to treat (e.g. atropine/glycopyrrolate as clinically appropriate).
• Recurarisation is uncommon but can happen if under-dosed or if ongoing absorption of relaxant continues; keep monitoring and reassess if weakness returns.
• Renal impairment: sugammadex–rocuronium complex is renally cleared; use with caution in severe renal failure (local policy may advise avoidance).
• Drug interaction: can reduce effectiveness of hormonal contraception—advise ‘missed pill’ type precautions (typically additional barrier contraception for 7 days) and document counselling.

If you need to re-paralyse after sugammadex

• Sugammadex binds rocuronium/vecuronium, so re-dosing rocuronium soon after may be ineffective or unpredictable.
• If re-paralysis is needed soon after sugammadex, consider an alternative agent not bound by sugammadex (e.g. atracurium/cisatracurium) and use neuromuscular monitoring.
• If rocuronium must be used again, senior input is advised; onset may be delayed and higher doses may be required—monitor closely.

Documentation and handover essentials

• Record: relaxant used, depth of block (TOF/PTC), sugammadex dose (mg and mg/kg), response (TOF ratio), and any adverse effects.
• If contraception advice is relevant, document that counselling was given.
• If any suspected reaction (rash, bronchospasm, hypotension), document clearly and escalate for follow-up.